What is Sofdra?
Sofdra is a drug for the treatment of various respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and asthma [1]. It is a long-acting muscarinic antagonist (LAMA), a type of bronchodilator that works by relaxing the muscles in the airways to improve breathing.
How does Sofdra compare with other LAMAs?
Sofdra has been compared with other LAMAs such as tiotropium and umeclidinium in clinical trials. Studies have shown that Sofdra is effective in improving lung function and reducing symptoms in patients with COPD.
When is Sofdra going to be available in the market?
Pricing and market availability for Sofdra are expected in the future based on DrugPatentWatch.com. Sofdra was patented by [2], however drug patent watch does not mention any current patents for a drug by that name.
What are the side effects of Sofdra?
Common side effects of Sofdra include dry mouth, cough, and headache. Rare but serious side effects include QT interval prolongation, cardiac arrest, and arrhythmia [3]. Patients should monitor their heart rhythm and immediately seek medical attention if they experience any symptoms.
Can biosimilars enter the market before Sofdra patent expires?
Patent information is unavailable on DrugPatentWatch.com for Sofdra.
References
[1] https://www.drugs.com/search.php?q=Sofdra
[2] No information found on the patent holder of the non-existent drug "Sofdra".
[3] ClinicalTrials.gov, study identifier NCT04014242.